The dangers of blue light: what is it and how can we protect against its threat?

A growing body of medical research is beginning to focus on the role played by harmful blue light in damaging the eye, leading to conditions like age-related macular degeneration (AMD).

This has been prompted by two global factors: an ageing population and a younger generation making regular, heavy use of blue light-emitting technology.

In this whitepaper we examine the effects of blue light, the eye’s natural resistance to it, and how that resistance can be bolstered.

Blue light whitepaper download
ophthalmic instruments, glaucoma, macular degeneration

Visionary medicine: the future of glaucoma treatments

Our new whitepaper explores how conventional treatments (surgical and medicine-based) tackle existing challenges of the conditions, and the limitations they face.

Glaucoma screening: a global perspective

What are the risk factors for glaucoma and how can identifying them guide creation of robust screening programmes?

60 million people live with glaucoma worldwide, and close to 5 million people are blind from open angle glaucoma. Glaucoma is prevalent and presents many challenges for the eye health industry. Our whitepaper examines open angle and angle closure glaucoma from a global perspective , looking at:

  • The prevalance of glaucoma
  • Genetic and age-related risk factors
  • Glaucoma screening in practice
ophthalmic instruments, glaucoma, macular degeneration

Age-related macular degeneration: the case for early screening

Our whitepaper explores the development of AMD and helps you to understand the key risk factors. Our analysis spans non-modifiable risk factors such as family history and genetic, as well as modifiable factors like smoking, diet and BMI.

Read our paper for insights into:

  • The academic case for targeted screening
  • Lifestyle factors affecting AMD development
  • Understanding wet and dry AMD
  • How ophthalmologists can raise awareness of AMD

The use of MPS ll as part of a macular screening programme

Prevention is better than intervention

This whitepaper outlines pragmatic guidelines for a coherent strategy around the prevention and management of age-related macular degeneration (AMD).

Written by Dr. Scott Mackie, a Consultant Ophthalmologist, supported by Elektron Eye Technology.